Botulinum Toxin Type A in Diabetic Peripheral Neuropathy

• Status: Completed
• Trial end date: 2022-03-08
• Target enrollment: 0
• Participant gender: All

Summary

Background: Diabetes mellitus is commonly complicated by diabetic peripheral neuropathy. Due to common side effects and poor tolerance to medication, poor adherence to medication is common in diabetic peripheral neuropathy. Botulinum toxin A intradermal injection has proved efficacy in cases of diabetic peripheral neuropathy however there is a need to compare its effect with other lines of treatment. The aim of the study was to compare botulinum toxin type a verses conventional oral treatment as a second line treatment of painful diabetic peripheral neuropathy. we conducted a comparative study on 30 patients with type 2 diabetes mellitus proved by nerve conduction study on carbamazepine. Patients were divided randomly into 3 groups. First group was add on duloxetine, second was add on gabapentin and the third group was injected intradermal with botulinum toxin A.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alexandria University
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; Duloxetine Hydrochloride; Gabapentin

Criteria

Inclusion Criteria:

• diabetic patients type 2 were included on single line of treatment with carbamazepine

Exclusion Criteria:

• any sever medical condition that might interfere with the results.